July 15, 2016 By Erica Lessem In the past year, the development of new tuberculosis (TB) drug candidates experienced some setbacks as well as some wise pruning, with the unexpected suspension of enrollment in STAND (a phase III combination trial…
July 15, 2016 By Mike Frick After decades of receiving short shrift from most national TB programs and international organizations, tuberculosis (TB) prevention is finally coming into the mainstream. In 2015, the World Health Organization (WHO) published its first-ever Guidelines…
July 15, 2016 By Erica Lessem INTRODUCTION Over the past decade, several new options for improving TB diagnosis have become available. The past year saw considerably more progress than the previous one. However, the reality of how most TB is…
February 2013 Update On Feburary 4, 2013, results from the phase IIb trial of the MVA85A vaccine in infants in South Africa (given as a booster following BCG immunization) were published in the Lancet. The vaccine proved safe but, disappointingly,…
Updates to this chapter can be found in the postscript at the end of this page. Original Report July 2012 By Erica Lessem Introduction Tuberculosis (TB) persists as a global health problem, suffering from both insufficient funding and political will…
April 10, 2019 – Tuberculosis (TB) is the number-one killer of people living with HIV. Using TB lipoarabinomannan (LAM) tests, an inexpensive, urine-based test, has been proven to decrease mortality rates and allow for earlier diagnosis among people living with…
TAG’s executive director Mark Harrington spoke at the U.S. Senate briefing held on March 28, 2019, not long after World TB Day. He invoked the stories of leaders that had tuberculosis, such as Eleanor Roosevelt and Nelson Mandela, on the…
Treatment Action Group (TAG) opposes the President's FY 2020 budget proposal, which makes a mockery of the administration's purported strategy to end AIDS in the United States over the next decade.
Treatment Action Group (TAG) welcomes the exciting news of a novel tuberculosis (TB) drug entering priority review by the Food and Drug Administration (FDA). Pretomanid represents only the fourth new TB drug to go through stringent regulatory review in the past half a century, and the first developed by a not-for-profit organization.
In our two briefs, Closing the Gap in Tuberculosis Research and Development Funding: Actions for U.S. Government Executive Agencies and Actions for U.S. Congress, we detail how a funding increase of 0.1 percent, based on "fair share" of research capacity, would close the funding gap in TB R&D, catalyze new public health tools we need to create positive health outcomes among communities vulnerable to TB worldwide.